

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAREPTA THERAPEUTICS, INC.,
Petitioner

v.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,
Patent Owner
and REGENXBIO INC.,
Exclusive Licensee

Case IPR2024-00580
U.S. Patent No. 11,680,274

EXCLUSIVE LICENSEE'S MANDATORY NOTICES

Pursuant to 37 C.F.R. § 42.8, the Exclusive Licensee, REGENXBIO INC.

(“REGENXBIO”), hereby submits the following Mandatory Notices in response to the Petition for *Inter Partes* Review of U.S. Patent No. 11,680,274 (“the ’274 Patent”).

1. Real Party-In-Interest under 37 CFR § 42.8(b)(1)

The Trustees of the University of Pennsylvania (“University” or “Patent Owner”) holds title to the ’274 Patent. On May 31, 2002, University granted GlaxoSmithKline LLC (“GSK”) an exclusive, royalty-bearing, worldwide right and license, with the right to grant sublicenses, to various intellectual property rights, including the ’274 Patent. On February 24, 2009, subject to certain limitations relating to the patents licensed to GSK, University granted REGENXBIO (under its former name ReGenX) an exclusive, royalty-bearing, worldwide right and license, with the right to grant sublicenses, to various intellectual property rights. On March 6, 2009, GSK granted REGENXBIO (under its former name ReGenX) an exclusive, royalty-bearing, worldwide right and license, with the right to grant sublicenses, to various intellectual property rights, including the ’274 Patent. Each of University, REGENXBIO, and GSK are real parties-in-interest in this matter.

2. Related Matters under 37 CFR § 42.8(b)(2)

The '274 Patent is the subject of the following civil action: *REGENXBIO Inc. f/k/a ReGenX et al v. Sarepta Therapeutics, Inc. et al.*, Case No. 1-23-cv-00667, (D. Del.). REGENXBIO is not aware of any disclaimers or reexamination certificates involving the '274 Patent. At the time of filing these mandatory notices, no other judicial or administrative matters may affect or be affected by a decision in this proceeding.

3. Lead and Back-Up Counsel, under 37 CFR § 42.8(b)(3)

REGENXBIO designates the following lead and back-up counsel:

LEAD COUNSEL	BACK-UP COUNSEL
Susan E. Morrison, Reg. No. 56,332 Fish & Richardson P.C. 60 South Sixth Street, Suite 3200 Minneapolis, MN 55402 Tel: 202-783-5070/Fax: 877-769-7945 Email: IPR47889-0035IP1@fr.com	Casey M. Kraning, <i>Pro Hac Vice</i> Deanna J. Reichel, <i>Pro Hac Vice</i> Fish & Richardson P.C. 60 South Sixth Street, Suite 3200 Minneapolis, MN 55402 Tel: 202-783-5070/Fax: 877-769-7945 Email: IPR47889-0035IP1@fr.com

4. Service Information under 37 CFR § 42.8(b)(4)(i) et seq.

Please address all correspondence and service to the address of counsel listed above. REGENXBIO also consents to electronic service by email at IPR47889-0035IP1@fr.com (referencing No. 47889-0035IP1).

Respectfully submitted,

Dated: March 13, 2024

/Susan E. Morrison/

Susan E. Morrison, Reg. No. 56,332

Casey M. Kraning (*pro hac vice forthcoming*)

Deanna J. Reichel (*pro hac vice forthcoming*)

Fish & Richardson P.C.

60 South Sixth Street, Suite 3200

Minneapolis, MN 55402

Attorneys for REGENXBIO Inc.

CERTIFICATE OF SERVICE

Pursuant to 37 CFR §§ 42.6(e)(4) and 42.205(b), the undersigned certifies that on March 13, 2024, a complete and entire copy of this Exclusive Licensee's Mandatory Notices and Power of Attorney were provided by email to the Petitioner by serving the correspondence address of record as follows:

Quinn Emanuel Urquhart & Sullivan, LLP

51 Madison Avenue, 22nd Floor
New York, New York 10010

Robert Wilson, Reg. No. 45,227

robertwilson@quinnemanuel.com

Anne Toker, Reg. No. 53,692

annetoker@quinnemanuel.com

James Glass, Reg. No. 46,729

jimglass@quinnemanuel.com

Tel.: 212-849-7000

/Hoi Cheung/

Hoi Cheung

Fish & Richardson P.C.

60 South Sixth Street, Suite 3200

Minneapolis, MN 55402

hcheung@fr.com